Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions

American Journal of Clinical Pathology

Volumn 131, Issue 6, 2009, Pages 782-787

  Gambichler, Thilo ^a   Grothe, Sarah ^a   Rotterdam, Sebastian ^a   Altmeyer, Peter ^a   Kreuter, Alexander ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Carcinoembryonic antigen; Cell adhesion molecules; Malignant melanoma; Melanocytic nevus

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DYSPLASTIC NEVUS; FEMALE; HUMAN; HUMAN TISSUE; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT;

ADULT; ANTIGENS, CD; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; DISEASE PROGRESSION; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; PRECANCEROUS CONDITIONS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 67149131793     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP24KXJVBZXENS     Document Type: Article

References (26)

1. Cummins DL, Cummins JM, Pantle H, et al. Cutaneous malignant melanoma. Mayo Clin Proc. 2006;81:500-507.
2. Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol. 1995;33:1000-1007.
3. Gimotty PA, Botbyl J, Soong SJ, et al. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2005;23:8065-8075.
4. Haass NK, Smalley KS, Li L, et al. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005;18:150-159.
5. Markel G, Gruda R, Achdout H, et al. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J Immunol. 2004;173:3732-3739.
6. Keijser S, Missotten GS, Bonfrer JM, et al. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol. 2006;90:213-217.
7. Markel G, Lieberman N, Katz G, et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 2002;168:2803-2810.
8. Markel G, Wolf D, Hanna J, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest. 2002;110:943-953.
9. 3. Am J Pathol. 2001;159:537-546.
10. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530-2536.
11. Ebrahimnejad A, Streichert T, Nollau P, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol. 2004;165:1781-1787.
12. Thies A, Berlin A, Brunner G, et al. Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases. Cancer Lett. 2007;248:68-80.
13. Markel G, Seidman R, Cohen Y, et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack [published online ahead of print June 13, 2008]. Immunology. 2009;126:186-200.
14. Thies A, Mauer S, Fodstad O, et al. Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice. Br J Cancer. 2007;96:609-616.
15. Egawa K, Honda Y, Kuroki M, et al. The carcinoembryonic antigen (CEA) family (CD66) expressed in melanocytic naevi is not expressed in blue naevuscell naevi in dendritic type. J Cutan Pathol. 2000;27:351-358.
16. Ben-Izhak O, Levy R, Weill S, et al. Anorectal malignant melanoma: a clinicopathologic study, including immunohistochemistry and DNA flow cytometry. Cancer. 1997;79:18-25.
17. Ben-Izhak O, Stark P, Levy R, et al. Epithelial markers in malignant melanoma: a study of primary lesions and their metastases. Am J Dermatopathol. 1994;16:241-246.
18. Selby WL, Nance KV, Park HK. CEA immunoreactivity in metastatic malignant melanoma. Mod Pathol. 1992;5:415-419.
19. Pavoni E, Flego M, Dupuis ML, et al. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. BMC Cancer. 2006;6:41.
20. Ravindranath MH, Shen P, Habal N, et al. Does human melanoma express carcinoembryonic antigen? Anticancer Res. 2000;20:3083-3092.
21. Sanders DS, Evans AT, Allen CA, et al. Classification of CEA-related positivity in primary and metastatic malignant melanoma. J Pathol. 1994;172:343-348.
22. Markel G, Seidman R, Stern N, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol. 2006;177:6062-6071.
23. Obrink B. CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol. 1997;9:616-626.
24. Beauchemin N, Kunath T, Robitaille J, et al. Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells. Oncogene.1997;14:783-790.
25. Crowson AN, Magro CM, Sanchez-Carpintero I, et al. The precursors of malignant melanoma. Recent Results Cancer Res. 2002;160:75-84.
26. Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol. 2001;45:260-276.